Brought to you by 
Merck licenses NK-1 antagonist VPD737 to Tigercat Pharma
08 Mar 2019
Executive Summary
Virtual biotech start-up Tigercat Pharma Inc. received exclusive worldwide rights to Merck & Co. Inc.’s Phase II serlopitant (VPD737) for chronic pruritis (itching that lasts for more than six weeks).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com